Der Hautarzt

, Volume 57, Issue 11, pp 961–968

Antiretrovirale Therapieregime



Die Verfügbarkeit und Anwendung von wirksamen antiretroviralen Therapieregimen haben die Mortalität und Morbidität der HIV-Infektion dramatisch gesenkt. Die weitestgehende Hemmung der Virusreplikation durch eine antiretrovirale Therapie (ART) verhindert die Krankheitsprogression sowie die Resistenzentwicklung, führt zur Rückbildung HIV-bedingter Symptome und zur klinisch relevanten Immunrekonstitution. Mittlerweile sind über 20 antiretrovirale Substanzen in 4 Medikamentenklassen zugelassen. Die Infektion ist dadurch besser behandelbar, die ART ist jedoch schwieriger geworden. Eine Vielzahl von Kombinationen ist denkbar, von denen nur eine kleine Zahl sinnvoll ist. Indikationsstellung, Auswahl der individuell am besten geeigneten Therapie, Beratung des Patienten und Therapiemonitoring erfordern ein hohes Maß an Erfahrung im Umgang mit HIV-infizierten Patienten. Unter den modernen Therapieregimen wird beim adhärenten Patienten nur noch selten ein virologisches Versagen beobachtet.


HIV-Infektion Antiretrovirale Therapie Initialtherapie Therapieversagen Antiretrovirale Substanzen 

Antiviral treatment regimens


The availability and use of effective antiretroviral combination therapies has dramatically decreased the morbidity and mortality of HIV infection. Almost complete suppression of viral replication by antiretroviral therapy prevents disease progression and development of resistance, as well as leading to both regression of HIV-associated symptoms and clinically relevant immune reconstitution. More than 20 antiretroviral substances in four classes have been approved. As a result of the broad therapeutic options, HIV infection can be better treated. Although a high number of combinations can be conceived, only a small number is actually applicable. The decisions to start, monitor and change therapy have become even more difficult. The indication for treatment, the selection of the most suitable therapy for an individual, the counseling of the patient, and the monitoring of the success of treatment demand a high level of knowledge and experience. Virologic failures of modern antiretroviral therapy regimens are rare in adherent patients.


HIV infection Antiretroviral therapy Initial therapeutic regimen Virologic failure Antiretroviral agents 


  1. 1.
    Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V (2004) Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 18(6): 960–963CrossRefPubMedGoogle Scholar
  2. 2.
    Carr A, Samaras K, Burton S et al. (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12(7): F51–58CrossRefPubMedGoogle Scholar
  3. 3.
    Carr A, Miller J, Law M, Cooper DA (2000) A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14(3): F25–32CrossRefPubMedGoogle Scholar
  4. 4.
    Concorde Team (1994) MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 343(8902): 871–881CrossRefPubMedGoogle Scholar
  5. 5.
    d’Arminio A, Sabin CA, Phillips AN et al. (2004) Cardio- and cerebrovascular events in HIV-infected persons. AIDS 18(13): 1811–1817PubMedGoogle Scholar
  6. 6.
    DeJesus E, Herrera G, Teofilo E et al. (2004) Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 39(7): 1038–1046CrossRefPubMedGoogle Scholar
  7. 7.
    Delta-Team (1996) A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet 348(9023): 283–291CrossRefPubMedGoogle Scholar
  8. 8.
    Durant J, Clevenbergh P, Garraffo R et al. (2000) Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 14(10): 1333–1339CrossRefPubMedGoogle Scholar
  9. 9.
    Finzi D, Blankson J, Siliciano JD et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5(5): 512–517CrossRefPubMedGoogle Scholar
  10. 10.
    Fischl MA, Ribaudo HJ, Collier AC et al. (2003) A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 188(5): 625–634CrossRefPubMedGoogle Scholar
  11. 11.
    Garcia-Gasco P (2006) 48-weeks of the RESIST trials. AIDS Rev 8(1): 45PubMedGoogle Scholar
  12. 12.
    Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V (2002) Liver toxicity caused by nevirapine. AIDS 16(2): 290–291CrossRefPubMedGoogle Scholar
  13. 13.
    Gulick RM, Mellors JW, Havlir D et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337(11): 734–739CrossRefPubMedGoogle Scholar
  14. 14.
    Gulick RM, Ribaudo HJ, Shikuma CM et al. (2004) Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 350(18): 1850–1861CrossRefPubMedGoogle Scholar
  15. 15.
    Hammer SM, Vaida F, Bennett KK et al. (2002) Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 288(2): 169–180CrossRefPubMedGoogle Scholar
  16. 16.
    Harrington M, Carpenter CC (2000) Hit HIV-1 hard, but only when necessary. Lancet 355(9221): 2147–2152CrossRefPubMedGoogle Scholar
  17. 17.
    Ho DD (1995) Time to hit HIV, early and hard. N Engl J Med 333(7): 450–451CrossRefPubMedGoogle Scholar
  18. 18.
    Kempf DJ, Marsh KC, Kumar G et al. (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41(3): 654–660PubMedGoogle Scholar
  19. 19.
    Laessig KA, Lewis LL, Hammerstrom TS (2006) Tenofovir DF and emtricitabine vs. zidovudine and lamivudine. N Engl J Med 354(23): 2506–2508; author reply 2506–2508CrossRefGoogle Scholar
  20. 20.
    Lazzarin A, Clotet B, Cooper D et al. (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348(22): 2186–2195CrossRefPubMedGoogle Scholar
  21. 21.
    Mellors JW, Munoz A, Giorgi JV et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126(12): 946–954PubMedGoogle Scholar
  22. 22.
    Mocroft A, Katlama C, Johnson AM et al. (2000) AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 356(9226): 291–296CrossRefPubMedGoogle Scholar
  23. 23.
    Mocroft A, Youle M, Moore A et al. (2001) Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 15(2): 185–194CrossRefPubMedGoogle Scholar
  24. 24.
    Montaner JS, Harrigan PR, Jahnke N et al. (2001) Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 15(1): 61–69CrossRefPubMedGoogle Scholar
  25. 25.
    Raboud JM, Montaner JS, Conway B et al. (1998) Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 12(13): 1619–1624CrossRefPubMedGoogle Scholar
  26. 26.
    Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM (2003) Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 83(1): 1–9CrossRefPubMedGoogle Scholar
  27. 27.
    Salzberger B, Marcus U, Vielhaber B et al. (2004) German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004). Eur J Med Res 9(11): 491–504PubMedGoogle Scholar
  28. 28.
    Staszewski S, Morales-Ramirez J, Tashima KT et al. (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 341(25): 1865–1873CrossRefPubMedGoogle Scholar
  29. 29.
    Walmsley S, Bernstein B, King M et al. (2002) Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346(26): 2039–2046CrossRefPubMedGoogle Scholar
  30. 30.
    Wood E, Hogg RS, Yip B et al. (2004) The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 35(3): 261–268PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Klinik für Dermatologie, Venerologie und AllergologieUniversitätsklinikum EssenEssen

Personalised recommendations